Last reviewed · How we verify
NCT05491447
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
Phase 2 trial testing BMX-010 in Atopic Dermatitis in 103 participants. Terminated before completion.
30 December 2023
Quick facts
| Lead sponsor | BioMimetix JV, LLC |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 103 |
| Start date | 8 January 2023 |
| Primary completion | 30 December 2023 |
| Estimated completion | 15 April 2024 |
| Sites | 19 locations across United States |
Drugs / interventions tested
- BMX-010 — full drug profile →
- Placebo
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
BioMimetix JV, LLC — full company profile →
Who can join
18 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase 2 clinical trial conducted in 2 parts: Part 1 - Pharmacokinetics and Part 2 - Randomized and Placebo Controlled (subject and clinical assessors will be blinded). Study Product will be applied to AD BID days 1-28. There will be weekly visits from Baseline (day 1) through Day 29. There is a final follow up visit 2 weeks after.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05491447
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BMX-010
Trials testing the same drug.
- NCT03381625 — Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis · Phase 2 · completed
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other BioMimetix JV, LLC trials
Trials by the same sponsor.
- NCT06620029 — BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT03752242 — Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris. · Phase 2 · terminated
- NCT03608020 — A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy · Phase 1, PHASE2 · terminated
- NCT02655601 — Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 · Phase 1, PHASE2 · completed
- NCT03381625 — Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05491447 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioMimetix JV, LLC
- Last refreshed: 18 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05491447.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing